Takeda Pharmaceutical Net Worth

Takeda Pharmaceutical Net Worth Breakdown

  TAK
The net worth of Takeda Pharmaceutical Co is the difference between its total assets and liabilities. Takeda Pharmaceutical's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Takeda Pharmaceutical's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Takeda Pharmaceutical's net worth can be used as a measure of its financial health and stability which can help investors to decide if Takeda Pharmaceutical is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Takeda Pharmaceutical Co stock.

Takeda Pharmaceutical Net Worth Analysis

Takeda Pharmaceutical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Takeda Pharmaceutical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Takeda Pharmaceutical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Takeda Pharmaceutical's net worth analysis. One common approach is to calculate Takeda Pharmaceutical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Takeda Pharmaceutical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Takeda Pharmaceutical's net worth. This approach calculates the present value of Takeda Pharmaceutical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Takeda Pharmaceutical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Takeda Pharmaceutical's net worth. This involves comparing Takeda Pharmaceutical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Takeda Pharmaceutical's net worth relative to its peers.
To determine if Takeda Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Takeda Pharmaceutical's net worth research are outlined below:
Takeda Pharmaceutical generated a negative expected return over the last 90 days
Takeda Pharmaceutical has a strong financial position based on the latest SEC filings
Latest headline from globenewswire.com: HUTCHMED Announces Launch by Takeda of FRUZAQLA in Japan

Takeda Pharmaceutical Quarterly Good Will

5.16 Trillion

Takeda Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Takeda Pharmaceutical Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Takeda Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Know Takeda Pharmaceutical's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Takeda Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Takeda Pharmaceutical Co backward and forwards among themselves. Takeda Pharmaceutical's institutional investor refers to the entity that pools money to purchase Takeda Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Managed Asset Portfolios, Llc2024-09-30
1.6 M
Envestnet Asset Management Inc2024-09-30
1.4 M
Blackrock Inc2024-06-30
1.4 M
Causeway Capital Management Llc2024-09-30
1.3 M
Macquarie Group Ltd2024-06-30
M
Wells Fargo & Co2024-06-30
871.7 K
Bank Of America Corp2024-06-30
867.1 K
Jane Street Group Llc2024-06-30
603.8 K
Kayne Anderson Rudnick Investment Management Llc2024-06-30
585.8 K
Capital Research Global Investors2024-09-30
13.1 M
Morgan Stanley - Brokerage Accounts2024-06-30
10 M
Note, although Takeda Pharmaceutical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Takeda Pharmaceutical's market capitalization trends

The company currently falls under 'Large-Cap' category with a total capitalization of 42.42 B.

Market Cap

0.0

Project Takeda Pharmaceutical's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.03  0.03 
Return On Capital Employed 0.02  0.02 
Return On Assets 0.01  0.01 
Return On Equity 0.02  0.02 
The company has Net Profit Margin of 0.06 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.21 %, which entails that for every 100 dollars of revenue, it generated $0.21 of operating income.
When accessing Takeda Pharmaceutical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Takeda Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Takeda Pharmaceutical's profitability and make more informed investment decisions.

Evaluate Takeda Pharmaceutical's management efficiency

Takeda Pharmaceutical has Return on Asset of 0.0278 % which means that on every $100 spent on assets, it made $0.0278 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0415 %, implying that it generated $0.0415 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.03. The value of Return On Capital Employed is expected to slide to 0.02. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 15.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 435.2 B.
Last ReportedProjected for Next Year
Book Value Per Share4.6 K4.9 K
Tangible Book Value Per Share-1.5 K-1.5 K
Enterprise Value Over EBITDA 12.45  18.12 
Price Book Value Ratio 0.89  0.85 
Enterprise Value Multiple 12.45  18.12 
Price Fair Value 0.89  0.85 
Evaluating the management effectiveness of Takeda Pharmaceutical allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Takeda Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue
2.3459
Revenue
4.5 T
Quarterly Revenue Growth
0.127
Revenue Per Share
1.4 K
Return On Equity
0.0415

Takeda Pharmaceutical Corporate Filings

6K
31st of October 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
FWP
28th of June 2024
A written communication used by offering participants to offer securities to the public or to solicit securities transactions.
ViewVerify
27th of June 2024
Other Reports
ViewVerify
25th of April 2024
Other Reports
ViewVerify
Takeda Pharmaceutical time-series forecasting models is one of many Takeda Pharmaceutical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Takeda Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Takeda Pharmaceutical Earnings per Share Projection vs Actual

Takeda Pharmaceutical Corporate Directors

JeanLuc ButelIndependent DirectorProfile
Michel OrsingerIndependent DirectorProfile
Shiro KuniyaIndependent DirectorProfile
Toshiyuki ShigaIndependent DirectorProfile
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.049
Dividend Share
192
Earnings Share
0.59
Revenue Per Share
1.4 K
Quarterly Revenue Growth
0.127
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.